'%3e%3cpath%20d='M29.5529%2025.4577C28.9763%2024.0918%2028.1395%2022.8511%2027.0891%2021.8047C26.0419%2020.7553%2024.8014%2019.9186%2023.4361%2019.3408C23.4239%2019.3347%2023.4116%2019.3317%2023.3994%2019.3256C25.3039%2017.95%2026.5419%2015.7092%2026.5419%2013.1812C26.5419%208.99325%2023.1487%205.6001%2018.9608%205.6001C14.7729%205.6001%2011.3797%208.99325%2011.3797%2013.1812C11.3797%2015.7092%2012.6177%2017.95%2014.5222%2019.3286C14.51%2019.3347%2014.4977%2019.3378%2014.4855%2019.3439C13.116%2019.9216%2011.8871%2020.7501%2010.8325%2021.8078C9.78311%2022.8549%208.94642%2024.0954%208.36866%2025.4607C7.80106%2026.7974%207.49494%2028.2304%207.46687%2029.6823C7.46606%2029.7149%207.47178%2029.7474%207.4837%2029.7778C7.49563%2029.8082%207.51351%2029.8358%207.5363%2029.8592C7.55909%2029.8826%207.58633%2029.9011%207.6164%2029.9138C7.64648%2029.9265%207.67879%2029.933%207.71142%2029.933H9.54556C9.68007%2029.933%209.78706%2029.826%209.79011%2029.6945C9.85125%2027.3346%2010.7989%2025.1245%2012.4741%2023.4493C14.2073%2021.716%2016.5092%2020.7623%2018.9608%2020.7623C21.4124%2020.7623%2023.7143%2021.716%2025.4475%2023.4493C27.1227%2025.1245%2028.0703%2027.3346%2028.1315%2029.6945C28.1345%2029.829%2028.2415%2029.933%2028.376%2029.933H30.2102C30.2428%2029.933%2030.2751%2029.9265%2030.3052%2029.9138C30.3353%2029.9011%2030.3625%2029.8826%2030.3853%2029.8592C30.4081%2029.8358%2030.426%2029.8082%2030.4379%2029.7778C30.4498%2029.7474%2030.4555%2029.7149%2030.4547%2029.6823C30.4242%2028.2211%2030.1215%2026.7997%2029.5529%2025.4577ZM18.9608%2018.4391C17.5577%2018.4391%2016.2371%2017.8919%2015.2436%2016.8984C14.2501%2015.9049%2013.7029%2014.5843%2013.7029%2013.1812C13.7029%2011.7781%2014.2501%2010.4575%2015.2436%209.46401C16.2371%208.47052%2017.5577%207.92334%2018.9608%207.92334C20.3639%207.92334%2021.6845%208.47052%2022.678%209.46401C23.6715%2010.4575%2024.2187%2011.7781%2024.2187%2013.1812C24.2187%2014.5843%2023.6715%2015.9049%2022.678%2016.8984C21.6845%2017.8919%2020.3639%2018.4391%2018.9608%2018.4391Z'%20fill='white'/%3e%3c/g%3e%3c/svg%3e)
Dr. Marek Sarissky
'%3e%3cpath%20d='M22.1642%2019.0924C21.7317%2018.068%2021.1041%2017.1375%2020.3163%2016.3527C19.5309%2015.5656%2018.6006%2014.9381%2017.5766%2014.5048C17.5674%2014.5002%2017.5582%2014.4979%2017.5491%2014.4933C18.9774%2013.4616%2019.9059%2011.7811%2019.9059%209.88504C19.9059%206.74408%2017.3611%204.19922%2014.2201%204.19922C11.0792%204.19922%208.53429%206.74408%208.53429%209.88504C8.53429%2011.7811%209.46282%2013.4616%2010.8912%2014.4956C10.882%2014.5002%2010.8728%2014.5025%2010.8636%2014.5071C9.83652%2014.9404%208.91487%2015.5617%208.1239%2016.355C7.33685%2017.1404%206.70933%2018.0707%206.276%2019.0947C5.85031%2020.0972%205.62072%2021.172%205.59967%2022.2609C5.59905%2022.2853%205.60335%2022.3097%205.61229%2022.3325C5.62123%2022.3553%205.63465%2022.376%205.65174%2022.3935C5.66883%2022.4111%205.68926%2022.425%205.71182%2022.4345C5.73437%2022.444%205.7586%2022.4489%205.78308%2022.4489H7.15868C7.25956%2022.4489%207.3398%2022.3686%207.3421%2022.2701C7.38795%2020.5001%208.09868%2018.8425%209.35506%2017.5861C10.655%2016.2862%2012.3814%2015.5709%2014.2201%2015.5709C16.0588%2015.5709%2017.7852%2016.2862%2019.0852%2017.5861C20.3415%2018.8425%2021.0523%2020.5001%2021.0981%2022.2701C21.1004%2022.3709%2021.1807%2022.4489%2021.2815%2022.4489H22.6571C22.6816%2022.4489%2022.7058%2022.444%2022.7284%2022.4345C22.751%2022.425%2022.7714%2022.4111%2022.7885%2022.3935C22.8056%2022.376%2022.819%2022.3553%2022.8279%2022.3325C22.8369%2022.3097%2022.8412%2022.2853%2022.8406%2022.2609C22.8176%2021.165%2022.5907%2020.0989%2022.1642%2019.0924ZM14.2201%2013.8284C13.1678%2013.8284%2012.1773%2013.418%2011.4322%2012.6729C10.6871%2011.9278%2010.2767%2010.9374%2010.2767%209.88504C10.2767%208.83271%2010.6871%207.84227%2011.4322%207.09715C12.1773%206.35204%2013.1678%205.94165%2014.2201%205.94165C15.2724%205.94165%2016.2629%206.35204%2017.008%207.09715C17.7531%207.84227%2018.1635%208.83271%2018.1635%209.88504C18.1635%2010.9374%2017.7531%2011.9278%2017.008%2012.6729C16.2629%2013.418%2015.2724%2013.8284%2014.2201%2013.8284Z'%20fill='%238590A2'/%3e%3c/g%3e%3c/svg%3e)
Co-authors
Following
Followers
Research Focus & Metrics
Explore full metrics on Scilit
Academic Career Length
18Years (2009-Present)
(Calculated once Scilit publication data is synced: current year − year of first publication + 1)
Representative Publications
View All Publications14 March 2009 in Cellular and Molecular Neurobiology
Journal Article
VBVladimir Balik
Vladimir Balik
PMPeter Mirossay
Peter Mirossay
PBPeter Bohus
Peter Bohus
ISIgor Sulla
Igor Sulla
LMLadislav Mirossay
Ladislav MirossayMSMarek Sarissky
Marek SarisskyJournal Article
DKDominik Kľoc
Dominik KľocSKSlavomír Kurhajec
Slavomír KurhajecMHMykhailo Huniadi
Mykhailo HuniadiJSJán Sýkora
Ján SýkoraTGTomáš Guman
Tomáš GumanMSMarek Sarissky
Marek SarisskyThe signaling lymphocytic activation molecule (SLAM) receptor family (SLAMF) consists of nine glycoproteins that belong to the CD2 superfamily of immunoglobulin (Ig) domain-containing molecules. SLAMF receptors modulate the differentiation and activation of a wide range of immune cells. Individual SLAMF receptors are expressed on the surface of hematopoietic stem cells, hematopoietic progenitor cells, B cells, T cells, NK cells, NKT cells, monocytes, macrophages, dendritic cells, neutrophils, and platelets. The expression of SLAMF receptors was studied during normal B cell maturation. Several SLAMF receptors were also detected in cancer cell lines of B-lymphoid origin and in pathological B cells from patients with B cell chronic lymphoproliferative disorders (B-CLPD), the most frequent hematological malignancies in adults. This review summarizes current knowledge on the expression of SLAMF receptors and their adaptor proteins SAP and EAT-2 in B-CLPD. Several SLAMF receptors could be regarded as potential diagnostic and differential diagnostic markers, prognostic factors, and targets for the development of novel drugs for patients with B-CLPD.
1 January 2020 in Neoplasma
Journal Article
MKM. Kicova
M. Kicova
ZMZ Michalova
Z Michalova
MCM. Coma
M. Coma
JGJ. Gabzdilova
J. Gabzdilova
KDK. Dedinska
K. Dedinska
MSMarek Sarissky
Marek Sarissky +5
The expression of CD73 on pathological B-cells is associated with shorter overall survival of patients with CLL
21 November 2016 in Leukemia & Lymphoma
Journal Article
MČMatúš Čoma
Matúš ČomaETElena Tothova
Elena Tothova
TGTomas Guman
Tomas Guman
MHMartina Hajikova
Martina Hajikova
MGMaria Giertlova
Maria Giertlova
MSMarek Sarissky
Marek SarisskyChronic lymphocytic leukemia (CLL) is a neoplastic disorder characterized by the clonal expansion of malignant B cells which accumulate in the bone marrow and peripheral blood. CLL B cells are stro...
8 June 2019 in Anticancer Research
Journal Article
ZMZuzana Michalová
Zuzana Michalová
MČMatúš Čoma
Matúš Čoma
MKMiroslava Kičová
Miroslava Kičová
JGJuliana Gabzdilová
Juliana Gabzdilová
KDKinga Dedinská
Kinga Dedinská
MSMarek Sarissky
Marek Sarissky +5
Background/Aim: Galectins belong to the family of galactose-binding proteins known to play an important role in the processes of cell proliferation, differentiation, migration and neoplastic progression. Herein, we studied the expression of galectin-3 (Gal-3) in chronic lymphocytic leukemia (CLL). Materials and Methods: The expression of Gal-3 was analyzed by means of multiparametric flow cytometry in normal and pathological B-cells from peripheral blood and bone marrow samples of 67 patients with CLL. Results: Pathological B-cells expressed significantly higher levels of cytoplasmic Gal-3 than normal B-cells. Moreover, overexpression of cytoplasmic Gal-3 was observed in the prognostically poorest subgroup of CLL patients, namely those with 17p deletion. Conclusion: Our results indicate a possible role of galectin-3 in CLL pathophysiology and its potential value as a prognostic marker and therapeutic target.
18 June 2022 in European Pharmaceutical Journal
Journal Article
MHMykhailo Huniadi
Mykhailo Huniadi
SSSimon Salanci
Simon Salanci
JSJan Sykora
Jan Sykora
SKSlavomir Kurhajec
Slavomir Kurhajec
MSMarek Sarissky
Marek SarisskySAP and EAT-2 are intracellular adaptor proteins that link SLAMF receptors to downstream intracellular signalling pathways. Their expression and functions vary among different types of hematopoietic cells. The roles of SAP and EAT-2 in haematological malignancies are poorly understood. Here, we attempted to optimise a method for the detection of intracellular SAP and EAT-2 by flow cytometry. We found that using PerFix EXPOSE kit for cell fixation and permeabilization ensures optimal results in terms of staining intensity and signal-to-noise ratio.
About Me
Marek Šarišský has worked as a researcher in the Department of Pharmacology at the Faculty of Medicine, P.J. Šafárik University in Košice, Slovakia, since 1999. He holds a second degree in
pharmacy from the Faculty of Pharmacy, Comenius University in Bratislava, Slovakia, which
he obtained in 1998. In 2001, he obtained a PharmD in pharmacology from the Faculty of Pharmacy, Comenius University in Bratislava. He also holds a PhD in pharmacology from the Faculty of Medicine, P.J. Šafárik University in Košice, which he obtained in 2006.
In 2003, he participated in the Socrates-Erasmus student mobility program (Servicio General de Citometría, Centro de Investigación del Cáncer, Universidad de Salamanca, Spain). From 2007 to 2008 he also worked in the Department of Laboratory Medicine (Subdepartment of Clinical Immunology and Alergology), L. Pasteur University Hospital in Košice and from 2008 to 2020 in the Central Laboratory of Clinical Cytometry of the Faculty of Medicine, P.J. Šafárik University in Košice and Medirex, a.s.
Since 2007, he has been a member of the European Society for Clinical
Cell Analysis (ESCCA). His research focuses on clinical flow cytometry, leukemia and lymphoma immunophenotyping, and SLAMF receptors and other markers with potential diagnostic, prognostic, and therapeutic significance.